Nyrada Inc. (ASX:NYR)
Australia · Delayed Price · Currency is AUD 0.3000
-0.0050 (-1.67%)
Aug 8, 2025, 4:10 PM AEST
Nyrada Company Description
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke.
Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Contact Details
Address: Sydney Place Sydney, Delaware 2000 Australia | |
| Phone | 61 2 9498 3390 |
| Website | nyrada.com |
Stock Details
| Ticker Symbol | NYR |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000070195 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| James Bonnar | Chief Executive Officer |
| Cameron Peter Jones C.A. | Chief Financial Officer |
| Benjamin Evison Ph.D. | Chief Scientific Officer |
| Dimitri Burshtein | Investor Relations Manager |
| Mark Waring B.Sc., P.M.P. | Senior Vice President of US Operations |
| David James Franks BEc, C.A., F Fin, J.P. | Company Secretary |